The partnership will leverage Cynvenio's ClearID liquid biopsy test, which detects tumor cells from blood samples. The test aids clinicians in choosing optimal therapies for their patients and can accelerate patient enrollment in clinical trials.
Patients enrolled in Cure Forward and tested with ClearID will have direct access to their data. The test must be ordered by a physician.
"The barriers to personalized medicine are too high for too many patients," Cure Forward CEO Martin Naley said in a statement. "We help people find innovative testing options like the ClearID test from Cynvenio and then use those results to be more effective champions of their own care."
Cure Forward is newly formed and also forged a partnership with Paradigm.
Cynvenio announced on Wednesday it raised $25.5 million in a Series B financing round.